|
| N-benzyl-4-(5-bromo-1H-indol-3-yl)pyrimidin-2-amine |
|
Mycobacterium
Staphylococcus |
Biofilm
Biofilm |
Preclinical (in vitro)
Preclinical (in vitro) |
Huggins WM, et al. 2018. ACS Med Chem Lett; Zeiler MJ, et al. 2020. ChemMedChem; Brackett SM, et al. 2020. RSC Med Chem
|
|
Compound 7
(internal name in literature) |
|
Vibrio |
TCP (Toxin-coregulated pilus) |
Preclinical (in vitro) |
Woodbrey AK, et al. 2018. Biochemistry |
|
Compound 13
(internal name in literature) |
|
Vibrio |
TCP (Toxin-coregulated pilus) |
Preclinical (in vitro) |
Woodbrey AK, et al. 2018. Biochemistry |
|
| 5-({1-[(2-chloro-1,3-thiazol-5-yl)methyl]-1H-indol-3-yl}methylene)-1,3-dimethyl-2,4,6(1H,3H,5H)-pyrimidinetrione |
|
Yersinia |
TTSS secreted effectors |
Preclinical (in vitro) |
Hu X, et al. 2013. Bioorg Med Chem Lett |
|
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
